Health ❯ Healthcare ❯ Patient Safety

Adverse Effects

Liver Injury Reporting Mechanisms Treatment-Related Adverse Effects Medication Interactions Monitoring Clinical Outcomes Medication Risks Vision Loss Drug Side Effects Pancreatitis

3 ARTICLES

6d ago

FDA Approves Pirtobrutinib for Frontline Treatment of CLL and SLL

The decision follows randomized trial results showing a large progression‑free survival gain while regulators flagged important safety warnings and said overall survival data remain immature.

4 ARTICLES

last wk.

FDA Upgrades Vitruvias Thyroid Tablet Recall to Highest-Risk Class

8 ARTICLES

2w ago

FDA Elevates Vitruvias Thyroid Tablet Recall to Class I

5 ARTICLES

4w ago

Company Recalls Three Lots of Multi‑Dose Epinephrine Vials Over Contamination Concerns

6 ARTICLES

last mo.

Melatonin Lowers Chronic Musculoskeletal Pain, University of Sydney Analysis Finds

5 ARTICLES

3mo ago

Study Finds Small Rise in Smell and Taste Diagnoses Among People on GLP‑1 Diabetes Drugs

3 ARTICLES

4mo ago

FDA Approves Xocova as First U.S. Post-Exposure COVID-19 Antiviral

7 ARTICLES

4mo ago

MHRA Recalls Batch of Ramipril 2.5mg After Packaging Error

4 ARTICLES

4mo ago

Brazil Approves 24‑Hour Subcutaneous Levodopa Therapy for Advanced Parkinson

3 ARTICLES

5mo ago

MHRA Tightens Finasteride Safety Warnings, Adds Precaution for Dutasteride

8 ARTICLES

5mo ago

UK Regulator Caps Use of Nasal Decongestant Sprays at Five Days

8 ARTICLES

5mo ago

New CAR-T Designs Deliver Low-Dose Remissions and Expose a Senescence Risk

18 ARTICLES

5mo ago

Viatris Recalls One Lot of Xanax XR Nationwide After Tablets Fail FDA Dissolution Test

15 ARTICLES

5mo ago

Lilly’s Oral Foundayo Matches Insulin on Heart Safety in Major Diabetes Trial

Adverse Effects

FDA Approves Pirtobrutinib for Frontline Treatment of CLL and SLL

FDA Upgrades Vitruvias Thyroid Tablet Recall to Highest-Risk Class

FDA Elevates Vitruvias Thyroid Tablet Recall to Class I

Company Recalls Three Lots of Multi‑Dose Epinephrine Vials Over Contamination Concerns

Atorvastatin Cuts Major Cardiovascular Events by 30% in Adults 70 and Older

Vitruvias Recalls Lot of Thyroid Tablets Over 'Superpotent' Test Results

TGA Warns Popular GLP‑1 Drugs May Be Linked to Rare Optic‑Nerve Disorder

MHRA Strengthens Warnings on Botulinum Toxin After Rise in Hospitalisations

More Than 2.5 Million Lupin Eye Drop Bottles Recalled Nationwide

MHRA Warns Heat Can Damage Medicines and Medical Devices

Never miss stories about

Adverse Effects

Melatonin Lowers Chronic Musculoskeletal Pain, University of Sydney Analysis Finds

Study Finds Small Rise in Smell and Taste Diagnoses Among People on GLP‑1 Diabetes Drugs

FDA Approves Xocova as First U.S. Post-Exposure COVID-19 Antiviral

MHRA Recalls Batch of Ramipril 2.5mg After Packaging Error

Brazil Approves 24‑Hour Subcutaneous Levodopa Therapy for Advanced Parkinson

MHRA Tightens Finasteride Safety Warnings, Adds Precaution for Dutasteride

UK Regulator Caps Use of Nasal Decongestant Sprays at Five Days

New CAR-T Designs Deliver Low-Dose Remissions and Expose a Senescence Risk

Viatris Recalls One Lot of Xanax XR Nationwide After Tablets Fail FDA Dissolution Test

Lilly’s Oral Foundayo Matches Insulin on Heart Safety in Major Diabetes Trial

Never miss stories about

Adverse Effects